Second quarter results exceeded expectations with double-digit revenue growth and raised full-year guidance. Immunology and neuroscience segments drove performance, while the Apogee acquisition and new product approvals strengthen the long-term outlook.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.